Nick Beije
Overview
Explore the profile of Nick Beije including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isebia K, de Jong A, van Dessel L, de Weerd V, Beaufort C, Helmijr J, et al.
Mol Oncol
. 2025 Mar;
PMID: 40084488
Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing...
2.
Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, et al.
Cancer Cell
. 2024 Nov;
42(12):2113-2123.e4.
PMID: 39577422
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects. However, mechanisms underlying PARPi resistance are not fully understood. While acquired mutations restoring...
3.
Verschoor N, Bos M, Oomen-de Hoop E, Martens J, Sleijfer S, Jager A, et al.
Eur J Cancer
. 2024 Jun;
207:114159.
PMID: 38878446
Circulating tumor DNA (ctDNA) holds promise as a biomarker for guiding adjuvant treatment decisions in solid tumors. This review systematically assembles ongoing and published trials investigating ctDNA-directed adjuvant treatment strategies....
4.
Carmichael J, Figueiredo I, Gurel B, Beije N, Yuan W, Rekowski J, et al.
J Clin Invest
. 2024 Jun;
134(21).
PMID: 38833311
BACKGROUNDClinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports...
5.
Longoria O, Beije N, de Bono J
Semin Oncol
. 2023 Oct;
51(1-2):25-35.
PMID: 37783649
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread...
6.
Beije N, Abida W, Antonarakis E, Castro E, de Wit R, Fizazi K, et al.
Eur Urol
. 2023 Apr;
84(3):253-256.
PMID: 37087376
The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data...
7.
van Rees J, Wullaert L, Gruter A, Derraze Y, Tanis P, Verheul H, et al.
Front Oncol
. 2023 Feb;
13:1083285.
PMID: 36793616
Background: Circulating tumour DNA (ctDNA) has been established as a promising (prognostic) biomarker with the potential to personalise treatment in cancer patients. The objective of this systematic review is to...
8.
Starmans M, Ho L, Smits F, Beije N, de Kruijff I, de Jong J, et al.
J Pers Med
. 2022 May;
12(5).
PMID: 35629148
Approximately 25% of the patients with muscle-invasive bladder cancer (MIBC) who are clinically node negative have occult lymph node metastases at radical cystectomy (RC) and pelvic lymph node dissection. The...
9.
Bos M, Kraan J, Sleijfer S, Martens J, Beije N
J Clin Oncol
. 2021 Dec;
40(5):519-520.
PMID: 34878805
No abstract available.
10.
Vitale S, Helmijr J, Gerritsen M, Coban H, van Dessel L, Beije N, et al.
BMC Cancer
. 2021 Mar;
21(1):315.
PMID: 33761899
Background: Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect...